公开(公告)号：US20240226261A9

公开(公告)日：2024-07-11

申请号：US18386593

申请日：2023-11-02

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Elisabeth Marie Monique BERTAUD ,  Ralph Leon BIEMANS ,  Nicolas Jean Benoit MONIOTTE ,  Laurent Bernard Jean STRODIOT

IPC: A61K39/09 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6087

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

公开(公告)号：US20240181038A1

公开(公告)日：2024-06-06

申请号：US18283632

申请日：2022-03-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA ,  UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： Ventzislav Bojidarov VASSILEV ,  Corey MALLETT ,  Ronan ROUXEL ,  Normand BLAIS ,  Masaru KANEKIYO ,  Barney S. GRAHAM

IPC: A61K39/145 ,  A61K39/00 ,  A61K39/385 ,  A61P31/16 ,  C07K14/005

CPC classification number: A61K39/145 ,  A61K39/385 ,  A61P31/16 ,  C07K14/005 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2760/16122 ,  C12N2760/16134

Abstract: The present invention relates to a carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.

公开(公告)号：US11957749B2

公开(公告)日：2024-04-16

申请号：US16772194

申请日：2018-12-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia Ammendola ,  Babak Bayat ,  Clarisse Lorin ,  Ventzislav Bojidarov Vassilev ,  Alessandra Vitelli

IPC: A61K39/29 ,  A61K39/39 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/292 ,  A61K39/39 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/57 ,  C07K2319/40 ,  C12N2710/10343 ,  C12N2710/24143 ,  C12N2730/10122 ,  C12N2730/10134

Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.

公开(公告)号：US11951161B2

公开(公告)日：2024-04-09

申请号：US16815635

申请日：2020-03-11

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： William Ripley Ballou, Jr. ,  Arnaud Michel Didierlaurent ,  Robbert Gerrit Van Der Most

IPC: A61K39/395 ,  A61K39/015 ,  A61K39/04 ,  A61K39/29 ,  A61K39/00

CPC classification number: A61K39/015 ,  A61K39/04 ,  A61K39/292 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/575 ,  A61K2039/70 ,  C12N2730/10134 ,  Y02A50/30

Abstract: Methods of inducing an immune response comprising at least two administrations of an adjuvanted immunogenic composition, wherein the second administration contains reduced amounts of antigen and adjuvant.

公开(公告)号：US20240110926A1

公开(公告)日：2024-04-04

申请号：US18257412

申请日：2021-12-15

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Sonia BUDRONI ,  Simona RONDINI ,  Silvia ROSSI PACCANI

IPC: G01N33/68 ,  A61K45/00

CPC classification number: G01N33/6869 ,  A61K45/00 ,  G01N2333/525 ,  G01N2333/545 ,  G01N2800/122 ,  G01N2800/26 ,  G01N2800/52

Abstract: The present invention relates to antibiotic agents for use in the treatment of patients presenting with an exacerbation of chronic obstructive pulmonary disease (COPD). More particularly the present invention relates to antibiotic agents for use in the treatment of COPD exacerbations in patients that, through analysis, have been identified as having an increased concentration of the IL-1α and TNF-α cytokine biomarkers in a biological sample taken from said patient. The present invention is further directed to methods of diagnosing and methods of treating a patient presenting with an exacerbation of COPD, said methods including identifying 1 the patient is suffering from an exacerbation that is associated with a bacterial infection.

公开(公告)号：US11939357B2

公开(公告)日：2024-03-26

申请号：US17346362

申请日：2021-06-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Matthew Bottomley ,  Vega Masignani

IPC: C07K14/22 ,  A61K39/00 ,  A61K39/095

CPC classification number: C07K14/22 ,  A61K39/095 ,  A61K2039/575 ,  C07K2319/33

Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHpb which can be modified to enhance their properties.

公开(公告)号：US11932671B2

公开(公告)日：2024-03-19

申请号：US17245681

申请日：2021-04-30

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Matthew Bottomley ,  Enrico Malito ,  Manuele Martinelli ,  Maria Scarselli

IPC: A61P37/04 ,  A61K39/095 ,  C07K14/22 ,  A61K39/00

CPC classification number: C07K14/22 ,  A61K39/095 ,  A61K2039/523 ,  A61K2039/55511 ,  A61K2039/70

Abstract: Modified meningococcal fHbp polypeptides with increased stability.

公开(公告)号：US20240082379A1

公开(公告)日：2024-03-14

申请号：US18256749

申请日：2021-12-10

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Scilla Buccato ,  Maria Giuliani ,  Alfredo Pezzicoli ,  Marco Spinsanti

IPC: A61K39/095 ,  A61K39/02 ,  A61K39/102 ,  A61K39/104 ,  A61K39/108 ,  A61K39/112 ,  C12N15/70 ,  C12N15/74 ,  C12P1/04

CPC classification number: A61K39/095 ,  A61K39/0258 ,  A61K39/0275 ,  A61K39/099 ,  A61K39/102 ,  A61K39/104 ,  A61K39/1045 ,  A61K39/105 ,  A61K39/107 ,  C12N15/70 ,  C12N15/74 ,  C12P1/04

Abstract: The present invention relates to the field of hyper-blebbing Gram-negative bacterial cells which are genetically modified by modifying the rpsA gene, the rpsA operon and/or 30S ribosomal protein S1 and to native outer membrane vesicles (nOMVs) obtained or obtainable from said genetically modified bacterial cells.

公开(公告)号：US20240076318A1

公开(公告)日：2024-03-07

申请号：US18358350

申请日：2023-07-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefania CAPONE ,  Antonella FOLGORI ,  Armin LAHM ,  Benjamin WIZEL

IPC: C07K14/005 ,  A61K39/245 ,  C12N7/00

CPC classification number: C07K14/005 ,  A61K39/245 ,  C12N7/00 ,  A61K2039/70

Abstract: The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

公开(公告)号：US20240026407A1

公开(公告)日：2024-01-25

申请号：US18039514

申请日：2021-12-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Murray BROWN ,  Edward CHAPMAN ,  Andrew COLLIS ,  Douglas FUERST ,  Joseph HOSFORD ,  Christopher MACDERMAID ,  James MORRISON

IPC: C12P19/14 ,  C12N9/42 ,  C12N9/24 ,  A61K39/39

CPC classification number: C12P19/14 ,  C12N9/2445 ,  C12Y302/01021 ,  C12N9/2402 ,  C12Y302/0104 ,  A61K39/39 ,  A61K2039/55577

Abstract: Methods for the enzymatic modification of saponins, products made thereby, uses of said products and also to other associated aspects. The saponins may be extracts of Quillaja species, such as extracts of Quillaja saponaria Molina.